NPM1 and acute myeloid leukemia: In patients with NPM1 mutated (NPM1mut) AML receiving either azacitidine or LDAC, CR/CRi was achieved in 78%, 18-month OS was 50%, and the median OS was 17.2 months (supplemental Table 4).